US Prescriptions During COVID-19: Hydroxychloroquine Soars, CVD Drugs Stable
Physicians latched quickly onto hopes that antimalarial drugs could help, but weren’t swayed by ACE inhibitor/ARB theories.
Related Articles
Public Comment Period Opens for New CV Medicine Board
For the next 3 months, individuals can weigh in on the effort to move certification of cardiologists away from the ABIM.
Lower Mortality With M-TEER vs Surgery, but Devil Is in the Details
A deep dive into a French study shows the benefit was seen in older, sicker patients who were at high risk for surgery.
Medical Imaging Has a Climate Problem: Radiologists Outline a Plan
Coinciding with Earth Day, a new paper tackles how imagers can improve sustainability, while preparing for environmental crises.
BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI
Prominent trialists took issue with the primary endpoint, how it was powered, and what effect COVID-19 and Katsanos played.
TCTMD’s Quick Takes: Dr. Julia Colombijn
Julia Colombijn, MSc, highlights the systematic underrepresentation of CKD patients in cardiovascular clinical trials.
Short Bouts of Physical Activity May Offset Occupational Sitting CVD Risks
Frequent bathroom breaks and setting timers to remind you to stand up can nudge people in the right direction, says Carl Lavie.
Pregnancy Complications Impart Higher Death Risk for Decades
Adverse pregnancy outcomes, though often overlooked by busy clinicians, should spur early prevention and close attention.
April 2024: Key Takeaways From ACC 2024
Hear some hot takes on REDUCE-AMI, ORBITA-COSMIC, PREVENT, and more of the top news this month.
Wearable-Tracked Walking Behavior Hints at Subclinical HF
Beyond step count, other measures like cadence and exercise capacity could detect an early signal before symptoms develop.
HeartMate II and 3 LVADs Recalled Due to Potential for Outflow Graft Obstruction
Initiated by Abbott/Thoratec and deemed Class I by the FDA, the recall is a response to reports of 273 injuries and 14 deaths.